Pefloxacin pharmacokinetics and serum bactericidal activities (SBA) against Escherichia coli and Staphylococcus aureus were compared after intravenous infusion of either a single 800-mg dose or twice-daily 400-mg doses into 16 healthy volunteers. Plasma pefloxacin concentrations were measured for up to 60 h, and SBAs were determined 1, 12 , and 24 h after the start of the infusion. The mean areas under the concentrationversus-time curve for plasma were not different (138 versus 136 h. mg/liter). The mean clearances, volumes of distribution, and half-lives were also comparable. The mean (± standard deviation) maximal concentration after the 800-mg infusion was 12.11 ± 1.35 versus 6.51 ± 0.73 mg/liter after the first 400-mg infusion and 7.42 +-0.76 mg/liter after the second 400-mg infusion. Mean trough concentrations at 24 h were significantly different: 2.77 ± 0.63 (800 mg) versus 1.93 ± 0.49 (400 mg twice) mg/liter (P = 0.0007). Mean SBAs against E. coli after 800 mg of pefloxacin were higher than 1/128 (1 h), 1/32 (12 h), and 1/16 (24 h). Mean SBAs against S. aureus under the same conditions were higher than 1/64 (1 h), 1116 (12 h), and 1/8 (24 h). Mean SBAs at 1 and 12 h were significantly higher after the 800-mg infusion than after the 400-mg infusion but were similar at 24 h for both regimens. Comparison of SBAs according to National Committee for Clinical Laboratory Standards criteria showed a similar adequacy at 24 h for both regimens against both strains. Administration of 800 mg of pefloxacin once a day is bioequivalent to 400 mg twice a day, and bactericidal activity of the 800-mg infusion is not less than that of two 400-mg infusions.
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Standards criteria showed a similar adequacy at 24 h for both regimens against both strains. Administration of 800 mg of pefloxacin once a day is bioequivalent to 400 mg twice a day, and bactericidal activity of the 800-mg infusion is not less than that of two 400-mg infusions.
Pefloxacin is a fluorinated quinolone that is especially active in vitro against gram-negative bacteria and staphylococcal strains (8) . Its excellent penetration into various tissues and fluids allows its use in a wide range of infections (8) . Pefloxacin is usually given as 400 mg twice a day (b.i.d.) intravenously or per os, resulting in similar maximum concentrations in plasma of approximately 10 mg/liter owing to its complete bioavailability (7) . Pefloxacin is metabolized extensively to form the active N-demethylpefloxacin (norfloxacin) and inactive N-oxide metabolites (9) . The elimination half-life (t1,2) of pefloxacin following administration of single doses ranged from 8 to 13 h, increasing to 14 to 15 h after multiple dosing (7) .
Thus, administration of 800 mg of pefloxacin once a day instead of 400 mg b.i.d. could be clinically effective and should improve compliance with treatment. The aim of this study was to compare pefloxacin pharmacokinetics and serum bactericidal activity (SBA) in 16 20, 40, 60, 65, 70, 80, 90, 120, 150, and 180 min and 4, 5, 7, 9, 12, 16, 24, 36, 48 , and 60 h after the start of the infusion. In the 400-mg series, blood samples were taken before infusion and then at 20, 40, 60, 65, 70, 80, 90, 120, 150 , and 180 min and at 4, 5, 7, 9 , and 12 h after the start of the first 400-mg infusion; they were also taken at 20, 40, 60, 65, 70, 80, 90, 120, 150, and 180 min and 4, 5, 7, 9, 12, 16, 24, 36 , and 48 h after the start of the second 400-mg infusion.
Plasma was separated and immediately stored at -20°C until pefloxacin was assayed for. Serum was separated from clotted blood in the samples taken just before infusion and at 1, 12 (i.e., before reinfusion in the 400-mg group), and 24 h after the start of the infusion for bactericidal activity determination.
Drug assay. The pefloxacin concentrations in plasma were measured by high-pressure liquid chromatography (10 (4) . Serum bactericidal titers were determined by using a modified version of the micromethod reported by Prober et al. (14) . Serial twofold dilutions of serum (from 1/2 to 1/1,024), made with heat-inactivated lyophilized human serum (Lyotrol NX Biomerieux) as the diluent, were deposited in the wells of microtiter plates, and an inoculum of 106 CFU/ml was added, with a final total volume of 100 ,ul. After 18 h of incubation at 37°C, 10 ,ul from each well was transferred onto Mueller-Hinton agar supplemented with Ca2' and Mg2e (Diagnostics Pasteur) and incubated for 18 h at 37°C. The bactericidal titer was the titer that resulted in a 99.9% reduction in CFU based on the CFU of the initial inoculum. The final inoculum was 104 per spot.
Titers are expressed as the inverse of the serum dilution; for example, 1/2 and 1/4, etc., are recorded as 2 and 4, etc., and 1 means no activity. Mean serum bactericidal titers were compared by using variance analysis after conversion of the titers to log base 2.
Results are also expressed according to the guidelines of the National Committee for Clinical Laboratory Standards (NCCLS) (11) The differences observed between the pharmacokinetic profiles after each mode of administration must be interpreted in the light of bactericidal activity results. Serum samples obtained prior to pefloxacin infusion did not show any bactericidal activity. Mean serum bactericidal titers measured 1, 12, or 24 h after the start of the infusion are reported in Table 2 . Bactericidal activities of residual C24 h were not significantly different in the two series for both strains. Conversely, bactericidal titers at 1 and 12 h were significantly higher after the 800-mg infusion than after the 400-mg infusion. These results were evaluated according to NCCLS criteria (Table 3) . At 12 h, SBAs against E. coli were adequate in 14 subjects after the 800-mg infusion versus 6 subjects after the 400-mg infusion. Against S. aureus, SBAs at 12 h were adequate in six subjects after the 800-mg infusion versus none after the 400-mg infusion. Comparison of bactericidal activity according to NCCLS criteria at 1 or 24 h showed no significant differences between the two schedules.
RESULTS
Mean plasma pefloxacin concentrations obtained with both dosage schedules are shown in Fig. 1 process would be concentration dependent and should have been observed in our study. Thus, it seems that saturation of pefloxacin metabolism is unlikely. Rather, time dependency of pefloxacin kinetics could be explained by self-or metabolite-mediated inhibition of metabolism. It should be noted that among the fluoroquinolones, increase in t1/2 and decrease in clearance after administration of multiple doses have been described for ciprofloxacin, which is the most-metabolized fluoroquinolone after pefloxacin (respectively, 40 and 85%) (1). Moreover, many cytochrome P-450 inhibitors have an imidazole ring or a nitrogen ring in their structures: allopurinol, cimetidine, isoniazid, ketoconazole, metronidazole, and phenylbutazone are well-known inhibitors (13) . The piperazine or quinoline ring of fluoroquinolones could be responsible for inhibition by the enzymes of their own metabolism. Since the mechanism of pefloxacin pharmacokinetic time dependency remains controversial, the accumulation ratio of 800 mg of pefloxacin given once daily for several days cannot be predicted.
Bioavailability of pefloxacin is considered to be nearly 100% (2, 10, 12, 18) , and primary pharmacokinetic parameters (CL and Vss) are not significantly different after oral or 1-h intravenous administration. Thus, it is expected that pharmacokinetic bioequivalence between the two schedules (400 mg twice versus 800 mg once) observed after a 1-h intravenous infusion would also hold after oral administration.
Finally, from a pharmacokinetic point of view, 800 mg once daily and 400 mg b.i.d. of pefloxacin were bioequivalent, the only significant difference being the C24 h for pefloxacin. However, the pefloxacin concentration kinetics of the two schedules were not superimposable, and the difference in their profiles had to be interpreted in terms of bactericidal activity.
With this aim in view, SBAs against two reference strains were used to determine the bioequivalence of the two regimens. Serum bactericidal titers were measured 1, 12, and 24 h after the start of the infusion. Serum bactericidal titers have been widely used since 1947 for antibiotic treatment monitoring in patients with endocarditis. The correlation between SBA and clinical outcome has been thoroughly investigated (20, 21) ; SBA was shown to be predictive of bacteriological eradication but not of bacteriological failure or clinical evolution. Thus, Wolfson and Swartz (22) Our results obtained after a 400-mg infusion of pefloxacin were similar to those of Van der Auwera et al. (19) : serum bactericidal titers at 12 h were 1/16 and 1/8 against E. coli and S. aureus, respectively. Comparison of mean serum bactericidal titers for each dosage regimen showed that 12 h after an 800-mg infusion of pefloxacin, these titers are higher than 1/32 against E. coli and 1/16 against S. aureus, and the difference with the 400-mg infusion is significant. Although the C24 hS were statistically different for the two regimens, they were not clinically different, as evidenced by the identical SBAs. These results demonstrate that the bactericidal activity of an 800-mg dose of pefloxacin given once a day should not be less than that of 400 mg of pefloxacin given b.i.d.
These results support the association of pefloxacin with 
